Literature DB >> 6191217

Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome.

K Oberg, K Funa, G Alm.   

Abstract

We treated nine patients who had carcinoid tumors of the small intestine, six of whom had the carcinoid syndrome, with daily intramuscular doses of leukocyte interferon--3 X 10(6) U per day for one month and 6 X 10(6) U per day for another two months. Seven patients had previously been treated with streptozocin and fluorouracil, without benefit. Treatment with interferon ameliorated the manifestations of the carcinoid syndrome and led to prompt and continuing decreases in urinary levels of 5-hydroxyindoleacetic acid and serum levels of human chorionic gonadotropin subunits and pancreatic polypeptide in all six patients with liver metastases, but it had no clear effect in two of three patients with only lymph-node involvement. After the treatment period, five of the six responders had relapses in clinical manifestations and increases in hormone levels. We conclude that interferon is of benefit in treating metastatic small intestinal carcinoid tumors in patients with the carcinoid syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6191217     DOI: 10.1056/NEJM198307213090301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  47 in total

1.  [2 year interferon therapy of metastatic carcinoid tumor].

Authors:  W von Scheidt; M Böhm; I Huber; R Habersetzer; K Jacob; A Markl; G Autenrieth
Journal:  Klin Wochenschr       Date:  1990-02-15

2.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 3.  Neuroendocrine tumors of the gastro-entero-pancreatic system.

Authors:  Sara Massironi; Valentina Sciola; Maddalena Peracchi; Clorinda Ciafardini; Matilde Pia Spampatti; Dario Conte
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 4.  Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2017-03

5.  Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha).

Authors:  A Karlsson-Parra; P Burman; H Hagberg; K Oberg; G Alm; L Klareskog; F A Karlsson
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

6.  Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.

Authors:  G Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; D D Von Hoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

Review 7.  Response of paraneoplastic syndromes to antineoplastic therapy.

Authors:  M Markman
Journal:  West J Med       Date:  1986-05

8.  An Interesting Case of Recurrent Small Bowel Obstruction.

Authors:  P B Allen; P De Cruz; M Efthymiou; A Fox; A C F Taylor; P V Desmond
Journal:  Case Rep Gastroenterol       Date:  2009-11-21

9.  Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.

Authors:  Su-Jung Kim; Jin Won Kim; Sae-Won Han; Do-Youn Oh; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

10.  Surgical treatment of mid-gut carcinoid tumors.

Authors:  C Makridis; K Oberg; C Juhlin; J Rastad; H Johansson; L E Lörelius; G Akerström
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.